Results 101 to 110 of about 1,473 (145)

Photoreceptor control of <i>Platynereis</i> growth and lifespan via evolutionarily conserved molecular pathways. [PDF]

Proc Natl Acad Sci U S A
Andreatta G, Scaramuzza F, Ćorić A, Orel L, Mat AM, Takekata H, Poehn B, Milivojev N, Tessmar-Raible K.   +8 more
europepmc   +1 more source

Characterization of the brain lipidome associated with frontotemporal lobar degeneration MAPT P301S mutation. [PDF]

J Lipid Res
Maroto-Juanes A, Vogels T, Koppes-den Hertog S, Loos M, Lütjohann D, Giera M, van der Kant R.   +6 more
europepmc   +1 more source

UHPLC-Q Exactive-Orbitrap-MS and network pharmacology analyses to investigate the mechanism by which Danggui-Shaoyao-San affects 27-OHC-induced cell damage in SH-SY5Y/C6 coculture. [PDF]

BMC Complement Med Ther
Huang Y, Zhai Y, Zhao D, Wu M, Shen Q, Zhao W, Wang Q, Yao L, Li W.   +8 more
europepmc   +1 more source

A review of the putative antiseizure and antiepileptogenic mechanisms of action for soticlestat. [PDF]

Epilepsia
Kondo S, Murthy V, Asgharnejad M, Benitez A, Nakashima K, Hawkins N, White HS.   +6 more
europepmc   +1 more source

Proteostasis disruption and lipid dyshomeostasis in neurodegeneration: exploring common druggable targets across sporadic and monogenic disorders. [PDF]

Front Mol Neurosci
Pereira Sena P, Friedrich L, Villarreal A, Fath F, Sopco L, Hernández-Guillamon M, Saraiva-Pereira ML, Britton G, Weber JJ, Schmidt T.   +9 more
europepmc   +1 more source

Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases [PDF]

Neurotherapeutics, 2019
Cholesterol 24-hydroxylation is the major mechanism for cholesterol removal from the brain and the reaction catalyzed by cytochrome P450 46A1 (CYP46A1), a CNS-specific enzyme. This review describes CYP46A1 in the context of cholesterol homeostasis in the brain and summarizes available experimental data on CYP46A1 association with different neurologic ...
Alexey M Petrov, Irina A Pikuleva, Pikuleva Irina A   +2 more
exaly   +3 more sources

CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease [PDF]

Brain, 2016
Huntington's disease is an autosomal dominant neurodegenerative disease caused by abnormal polyglutamine expansion in huntingtin (Exp-HTT) leading to degeneration of striatal neurons. Altered brain cholesterol homeostasis has been implicated in Huntington's disease, with increased accumulation of cholesterol in striatal neurons yet reduced levels of ...
Sandro Alves, Antonin Lamaziere, Anabelle Planques   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

CYP46A1 and the APOEε4 Allele Polymorphisms Correlate with the Risk of Alzheimer’s Disease

Molecular Neurobiology, 2018
Polymorphisms of the cholesterol-24S-hydroxylase (CYP46A1) and apolipoprotein E (APOE) genes are risk factors for Alzheimer's disease (AD). Plasma level of 24S-hydroxcholesterol (24-OHC), the metabolite of cholesterol, is thought to correlate with AD.
Fan Zeng, Yu-Hui Liu, Hui-Yun Li
exaly   +3 more sources